{"id":"W4362546308","doi":"10.1158/2159-8290.c.6549583.v1","title":"Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Sanofi Genzyme; Takeda Oncology; Genentech; Regeneron Pharmaceuticals; National Institutes of Health; Natera; Chugai Pharmaceutical; Seagen; Array BioPharma; OncoSec Medical; Pfizer; Incyte; AstraZeneca; Amarin Corporation; Castle Biosciences; National Cancer Institute; Foghorn Therapeutics; Gilead Sciences; Eisai; National Comprehensive Cancer Network; Sanofi; Jounce Therapeutics; Celgene; Bristol-Myers Squibb; Amgen; GlaxoSmithKline","keywords":"Pembrolizumab; Medicine; Ipilimumab; Adjuvant; Internal medicine; Melanoma; Adverse effect; Confidence interval; Adjuvant therapy; Oncology; Gastroenterology; Cancer; Immunotherapy; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003696309,0.000517787,0.001433501,0.0002401585,0.0002162239,0.000575442,0.0003723248,0.0005848355,0.002628004],"category_scores_gemma":[0.004055345,0.0002625343,0.002831891,0.0003864552,0.0004061698,0.0004329768,0.000254099,0.001357036,0.0004036204],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004836635,"about_ca_system_score_gemma":0.0005980264,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008059623,"about_ca_topic_score_gemma":0.002000927,"domain_scores_codex":[0.9981747,0.00125075,0.0001682205,0.0001183209,0.0002042885,0.0000837073],"domain_scores_gemma":[0.996161,0.001922729,0.0009315031,0.000370928,0.0001765452,0.0004372218],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8715396,0.003370005,0.02237994,0.002977951,0.008491083,0.0002328138,0.0001112989,0.002389329,0.009169031,0.0001748174,0.004031262,0.07513296],"study_design_scores_gemma":[0.4609419,0.2708869,0.2137716,0.001042548,0.0230512,0.001139554,0.000174468,0.002454816,0.00794906,0.0007808197,0.01771566,0.00009152421],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"dataset","genre_scores_codex":[0.9743544,0.01799286,0.0006062422,0.0007833514,0.0002473333,0.0003419147,0.003204106,0.00002743736,0.002442335],"genre_scores_gemma":[0.9917938,0.003669388,0.0003253154,0.0006010265,0.0001694551,0.0002126491,0.002346342,0.00001228147,0.0008697344],"genre_candidate":"dataset","genre_consensus":null,"teacher_disagreement_score":0.003696309,"threshold_uncertainty_score":0.01954818,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1433310800179343,"score_gpt":0.3625041683865247,"score_spread":0.2191730883685903,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}